THE APEX TIMES
Merck and Moderna to present Phase 3 INTerpath-001 results for intismeran plus KEYTRUDA at ESMO 2026
The companies said they will share detailed findings from a Phase 3 trial testing Moderna’s intismeran autogene as an add-on to Merck’s KEYTRUDA (pembrolizumab), with recurrence-free survival described as a key endpoint.
Merck and Moderna said they will present detailed results from a Phase 3 study, INTerpath-001, evaluating intismeran autogene in combination with KEYTRUDA (pembrolizumab) at the ESMO 2026 Presidential Symposium on Oct. 22, 2026.
The companies framed the upcoming presentation as a “landmark” readout from the trial, describing the findings as positive on recurrence-free survival, a measure of the length of time patients remain free from cancer returning after treatment.
Moderna’s role is tied to intismeran autogene, an investigational gene-based therapy being tested alongside KEYTRUDA, which is an immunotherapy drug used in multiple cancers. Merck, known as MSD outside the United States and Canada, is the developer of KEYTRUDA.
In the announcement tied to the presentation, Merck and Moderna did not specify in the public headline text the cancer type being studied, the trial population size, the length of follow-up, or the exact magnitude of the recurrence-free survival benefit.
They also did not disclose how the combination performed on other clinically important endpoints beyond recurrence-free survival in the text available for this report, such as overall survival, time-to-event measures other than recurrence-free survival, or detailed safety and tolerability results for the combination.
The companies’ decision to share “detailed” results at a high-profile oncology meeting suggests they expect the trial data to be decision-relevant for clinicians and payers, particularly because recurrence-free survival is often used as a proxy for long-term disease control in early-stage or adjuvant settings.
Within the broader oncology landscape, the push to combine immune checkpoint blockade with next-generation, gene-based therapeutics reflects a sustained effort to improve depth and durability of response. For Moderna, partnerships that move its platform assets into late-stage registrational settings are central to its strategy, while Merck’s development efforts aim to extend KEYTRUDA’s use across tumor types and treatment settings.
One caveat is that the public announcement text provided here does not include the quantitative results, statistical methods, hazard ratios, p-values, subgroup outcomes, or any safety tabulations. Those details are expected to be released through the conference materials when the presentation occurs. Until then, the market impact will likely hinge on how the final efficacy and safety data are presented and interpreted by the oncology community.
Why It Matters
- A Phase 3 readout framed as “positive” on recurrence-free survival can influence how quickly clinicians consider new combination strategies, particularly if the benefit is durable and safety is acceptable.
- KEYTRUDA remains one of the most widely used immunotherapies in oncology, and pairing it with a gene-based therapy could expand its role if results hold across subgroups.
- For Moderna, late-stage progress for an investigational asset can meaningfully affect market expectations for future cash flows, collaboration value, and platform validation.
- Investors and clinicians will likely focus on the specific magnitude of benefit and the breadth of results, since the public headline text does not include the key quantitative or safety details.
Sources
Key Facts
- Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) said they will present detailed Phase 3 results from the INTerpath-001 trial at the ESMO 2026 Presidential Symposium.
- The Phase 3 study evaluates intismeran autogene (Moderna) given in combination with KEYTRUDA (pembrolizumab, Merck).
- The companies described the trial outcome as positive for recurrence-free survival.
- The announcement language available here did not provide the cancer indication, patient numbers, follow-up duration, or the quantitative size of the recurrence-free survival benefit.
- The companies did not disclose in the provided text additional efficacy endpoints (such as overall survival) or detailed safety outcomes for the combination.
Healthcare Related
SpaceX Says It Aims to Add 200,000 Nvidia Chips Online Each Month, Echoing Nvidia CEO Jensen Huang’s Push for GPU-Backed Financing
The aerospace and satellite operator says it is on pace to bring large volumes of Nvidia accelerators into production use every month, tying its scale plans to a financing concept Nvidia executives have promoted.
Nasdaq-100 falls more than 3% as oil rises; Meta sell-off tied to earnings, Yahoo Finance says
A broad risk-off move pushed the Nasdaq-100 lower, with Meta among the laggards after the company’s earnings, while higher oil prices weighed on sentiment amid escalating geopolitical concerns.
Apple CEO John Ternus’ reported shareholding is tied to performance-based stock awards
A market recap published Oct. 22, 2026 says Apple’s CEO John Ternus holds Apple shares, with his potential additional equity driven by performance goals. Apple has not published a simple, stand-alone figure for an executive’s personal share count in its newsroom.
Lockheed Martin points to record backlog and strong cash generation as it reports double-digit Q3 growth
In commentary around its third-quarter results, Lockheed Martin said it delivered double-digit growth in sales and profit, generated about $3 billion in free cash flow, and pushed its backlog to a record $292 billion.
Goldman Warns of Potential Short Squeeze as Hedge Funds Increase Stock Shorting to Five-Year Highs
A surge in short selling has outpaced long buying by roughly five to one across global equities this month, according to commentary attributed to Goldman, raising the risk of a crowded squeeze if prices rise.
Union Pacific reports record third-quarter revenue and profit, citing stronger demand and pricing
The railroad operator said higher volumes and improved pricing helped offset pressures from rising fuel costs and broader inflation, as it announced results for the quarter ended this past period.
Elon Musk makes $1 billion investment in Skydance, the company formed to oversee CNN
The Tesla chief executive’s latest financial move links him to a newly formed media platform associated with CNN, according to a report citing the investment size and timing.
CodeCoin unveils a “quantum-secured” payment card using the Visa network at IMF meetings in Bangkok
The announcement, made during the IMF Annual Meetings, positions a new digital card as a security-forward option and ties it to a Visa network rails rollout, though specifics about the technology and Visa’s role were not disclosed in the post.
Costco’s membership model continues to draw investors as shares turn $1,000 into $8,018 over a decade, the comparison to the S&P 500 highlights the long-game
A new market comparison underscores how Costco’s membership-driven business has translated into outsized shareholder gains over ten years, even as the broader market delivered a more modest rise.
PepsiCo renews U.S. partnership with Taco Bell through 2036
PepsiCo said it has extended its U.S. partnership with Taco Bell, part of Yum Brands, through 2036, underscoring the continued importance of long-dated beverage agreements with large quick-service restaurant chains.
